Medilink Therapeutics

company

About

Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development.

  • Suzhou,Jiangsu,China

Details

Last Funding Type
Series B
Last Funding Money Raised
$70M
Industries
Biotechnology,Genetics,Therapeutics
Founded date
Jan 1, 2020
Operating Status
Active
Legal Name
Suzhou Medilink Therapeutics Ltd.
Also Known As
Suzhou Medilink Therapeutics

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$120M
Medilink Therapeutics has raised a total of $120M in funding over 2 rounds. Their latest funding was raised on Mar 14, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 14, 2022 Series B $70M 5 LYFE Capital
Qiming Venture Partners
Detail
Mar 1, 2021 Series A $50M 3 Apricot Capital
Loyal Valley Capital
Qiming Venture Partners
Detail

Investors

Number of Lead Investors
Number of Investors
5
6
Medilink Therapeutics is funded by 6 investors. LYFE Capital and Qiming Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
LYFE Capital Yes Series B
Qiming Venture Partners Yes Series B
Apricot Capital Yes Series A
Highlight Capital Series B
Legend Capital Series B
Loyal Valley Capital Series B

Employee Profiles

Number of Employee Profiles
1
Medilink Therapeutics has 1 current employee profiles, including Executive Tongtong Xue
Executive